Werewolf presents Phase 1/1b and 1b/2 clinical data for WTX-124 and WTX-330
Werewolf Therapeutics presented new clinical data for its cancer therapeutic candidates WTX-124 and WTX-330 at the SITC 2026 Annual Meeting, showing favorable safety profiles and antitumor activity in patients with highly advanced, treatment-refractory solid tumors.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed